Kaplan Fox urges investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) with significant losses to seek a leadership role before September 22, 2026. Aug. 5, 2026 7:30 PM ET Source: Kaplan Fox NEW YORK, NY - August 5, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation ("PROCEPT" or the "Company") (NASDAQ: PRCT) on behalf of all purchasers of PROCEPT common stock between February 28, 2024 and February 25, 2026 (the "Class Period"). If you are an investor in PROCEPT and have suffered losses, you may CLICK HERE to contact NewMediaWire LLC. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than September 22, 2026 to serve as a lead plaintiff for the purported class. If you have losses NewMediaWire LLC encourage you to contact NewMediaWire LLC to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery. The complaint alleges that contrary to defendants' Class Period assurances that the "differential" between handpiece unit sales and procedures had "remained relatively consistent," PROCEPT's discount program had caused handpiece orders to materially exceed procedures in every quarter during the Class Period. According to the complaint, these undisclosed sales tactics artificially inflated PROCEPT's reported U.S. handpiece unit sales and revenues by pulling forward demand at the expense of future periods. WHY CONTACT KAPLAN FOX? Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented. Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America - the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act - $800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch. For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes. If you have any questions about this Notice, your rights, or your interests, please contact: Laurence D. King KAPLAN FOX & KILSHEIMER LLP 1999 Harrison Street, Suite 1501 Oakland, California 94612 (415) 772-4704 [email protected] Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.

INVESTOR ALERT: Pomerantz law Firm reminds investors with losses on their investment in PROCEPT BioRobotics Corporation of class action lawsuit and upcoming deadlines - PRCT. 2 2 minutes read NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) - Pomerantz LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NASDAQ: PRCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. US news subscription The class action concerns whether Procept and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until September 22, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Procept securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com. On August 6, 2025, Procept announced earnings for its second fiscal quarter of 2025, revealing that Procept had only sold approximately 12,750 handpieces in the United States during the quarter. During Procept's earnings call, Chief Financial Officer Kevin Waters reported that Procept expected to ship approximately 13,350 units in the following quarter, significantly below consensus estimates of more than 13,840 units. Procept's quarterly handpiece sales guidance also implied that Procept would need to grow handpiece sales by approximately 25% year-over-year in the fourth quarter in order to meet Procept's annual unit sales guidance. In addition, then-Chief Executive Officer Reza Zadno revealed that Procept was eliminating the role of Chief Commercial Officer in order to "strengthen" Procept's "commercial execution." On this news, Procept's stock price fell approximately 16% over a two-day trading period. Then, on November 4, 2025, Procept announced earnings results for its third fiscal quarter of 2025, revealing that Procept had only sold 13,225 handpieces during the quarter, which missed Procept's sales guidance issued during the prior quarter. During the corresponding conference call, CFO Waters further revealed that Procept was reducing its annual handpiece sales guidance by 1,000 units, down from 53,000 units to 52,000 units to allow for the "optimization of field inventory." CEO Larry L. Wood further admitted that Procept had not "been managing customer inventory by establishing par levels" and that some customers were "probably carrying too much inventory." On this news, Procept's stock price fell more than 10% over a two-day trading period. Finally, on February 25, 2026, Procept announced earnings results for its fourth fiscal quarter and year ending December 31, 2025. Procept revealed that handpiece sales had materially exceeded procedures in every quarter since the first fiscal quarter of 2023, a differential which had consistently grown over time, ultimately resulting in cumulative excess field inventory of more than 10,000 units. Procept further revealed that quarterly handpiece unit sales in the United States had declined significantly from 13,225 units in the third quarter to 9,400 units, representing a sequential decline of nearly 30%. On this news, Procept's stock price fell more than 18% over a two-day trading period. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes.

PROCEPT faces class action for hidden sales practices. Unmasking PROCEPT's steep decline. You set your sights on a promising biomedical tech industry pick - PROCEPT BioRobotics, ticker NASDAQ:PRCT. But here Investors Hangout, LLC is staring at a near 50% stock value drop, and investors caught in this tumble have good reason to square up for a fight. Hagens Berman, that powerhouse firm known for plaintiff litigation, is stomping in with a class action against PROCEPT, citing misleading sales practices. Let's dig into what stinks in PROCEPT's closet. Discount games gone sour. The drama swirling around PROCEPT's stock woes centers on some sneaky sales tactics. The problem? An aggressive bulk discount program the company allegedly pushed, tempting customers into excessive orders at the end of each quarter. The grand approach led to sales that looked swell on paper but were yanking future numbers forward, potentially hoodwinking investors who thought they were peering into genuine growth. The crux of the lawsuit aims at these dirty little details - analysts and investors were none the wiser about how PROCEPT padded their stats. They held the fogged mirror of strong sales growth up for everyone to see, all the while propping it on unstable bases. Protracted consequences for investors. This ugly dance came to light when quarterly earnings reports hit with a brutal thud. Just a year ago, on August 6, 2025, PROCEPT revealed its Q2 performance. Repeatedly missing the mark on handpiece sales, the investors started catching on. Fast forward to Q3, another rough result set the market twitching - a slash in sales guidance, and insight into mismanaged inventories with customer stockpiles towering over market need. "That soap opera level scariness of watching PROCEPT crumble under its own misdirection says it flat out: unchecked greed overrode operational transparency," mused one industry vet reflecting on the stock's nosedive. * February 28, 2024 - February 25, 2026 are the hot dates; the investors stuck during this window can jump to lead the charge in the lawsuit. * On November 4, 2025, PROCEPT admitted its missteps - an overstuffed corner of undisclosed inventory building up from its shady discount strategy. Investor takeaway: navigate cautiously. Look, when the facade starts crumbling, it's never a pretty sight. If you're holding onto PRCT shares, you're deep in the pit of this financial drama. A 48% haircut to share value is enough to rile anyone and has an army of investors ready to pounce with legal action. But before hanging up the towel, consider your next move strategically. Look closely at what went sideways; those figures and faces in the quarterly reports tell tales more than fluff. PROCEPT investors need to weigh the reality - did they really see gains promised, or was it just a flickering mirage snuffed out by dubious practices? The road ahead may be blurred, but clarity in such environs often demands a hard, painful glance back at what the previous reports touted. Whistleblowers may hold the key. Here's another dimension: for anyone hanging onto insider scoops, the SEC Whistleblower program is dangling some decent carrots - could pack rewards up to a neat 30% of any funds clawed back. That's one heck of a silver lining for those stuck in the trenches of corporate deception. Whether you leap onto the court bandwagon or decide to bide the storm, know this: PROCEPT's story isn't unique. Companies dance around quarterly results to appease Wall Street's ceaseless drum, but when reality breaks, nothing shields missteps from the daylight. The message is blindingly clear - a sound investment strategy hangs on transparency and a personal commitment to reading between the lines before buying into the sector's sweet promises.